How Can an Early Phase 1 Clinical Trial Help Advance New Treatments?

Developing a new medicine involves a series of carefully controlled steps before it can become an approved treatment. One of the most important early stages is the Early Phase 1 Clinical Trial, where researchers begin collecting clinical data about an investigational medicine in humans.

For sponsors and drug developers, this stage can provide important information about how a new medicine behaves in the body, how it is tolerated, and what further clinical development may be appropriate. The evidence generated can help inform the design of subsequent studies and support more efficient decision-making throughout the development pathway.

For organisations developing innovative medicines, choosing an experienced early-phase clinical research partner can also make a meaningful difference. Scientia Clinical Research is a dedicated Phase I clinical trial unit in Sydney with experience across first-in-human studies, healthy volunteer research, patient studies, pharmacokinetic studies, pharmacodynamic studies and other early-phase designs.

What Is an Early Phase 1 Clinical Trial?

An Early Phase 1 Clinical Trial is an early-stage clinical study conducted in humans to generate initial clinical information about an investigational product.

These studies are commonly designed to investigate areas such as:

• Safety and tolerability

• Pharmacokinetics (PK), including how a medicine is absorbed, distributed, metabolised and eliminated

• Pharmacodynamics (PD), including how the medicine affects the body

• Dose-related responses

• Food effects or drug-drug interactions, where relevant

• Other information needed to guide subsequent clinical development

Depending on the investigational product and development strategy, early Phase I research may involve healthy volunteers or specific patient populations.

Scientia’s experience includes First-in-Human (FIH) studies, single ascending dose (SAD) and multiple ascending dose (MAD) studies, food-effect studies, drug-drug interaction studies, PK studies, biosimilar and vaccine studies, pharmacodynamic studies and specialised Phase I oncology research.

How Can Early Phase 1 Research Advance New Treatments?

The primary value of early clinical development is the generation of reliable human data that can guide the next stages of research.

1. Provides Initial Human Safety and Tolerability Data

Before an investigational medicine progresses into larger clinical studies, researchers need to understand how it behaves when administered to humans.

Early Phase I studies are designed with close medical monitoring and predefined safety assessments. This allows researchers to evaluate tolerability and identify safety findings that may influence later study designs.

Scientia highlights 24/7 participant monitoring and dedicated medical oversight as part of its early-phase research capabilities.

2. Helps Researchers Understand Pharmacokinetics

Pharmacokinetic data can provide insight into what happens to an investigational medicine after administration.

Researchers may assess parameters associated with:

• Drug absorption

• Exposure

• Distribution

• Metabolism

• Elimination

• Concentration over time

These findings can help inform decisions about dosing schedules and the design of subsequent clinical studies.

3. Supports Dose Selection and Study Design

Dose selection is an important part of early clinical development.

Depending on the study design, researchers may evaluate how participants respond to different dose levels. Data from these studies can help sponsors make informed decisions about doses and dosing regimens to investigate in later studies.

For example, SAD and MAD designs can provide different types of information about an investigational product following single or repeated administration. Scientia has experience conducting both types of First-in-Human studies.

4. Generates Data for Future Clinical Development

An early study does not operate in isolation. Its findings can influence the design of subsequent clinical research.

Data generated during early development may help sponsors consider:

• Appropriate dose ranges

• Sampling schedules

• Safety monitoring requirements

• PK and PD endpoints

• Participant populations

• Inclusion and exclusion criteria

• Subsequent study designs

This evidence-based approach can help sponsors make more informed development decisions as a medicine progresses through the clinical research pathway.

5. Helps Evaluate Drug-Drug and Food Interactions

Some investigational medicines require additional studies to understand whether food or other medicines influence their exposure or activity.

Early-phase research can include food-effect (FE) and drug-drug interaction (DDI) studies where scientifically and clinically appropriate.

Scientia lists both FE and DDI studies among its areas of Phase I experience.

6. Supports First-in-Human Development

For a new investigational product, the transition from preclinical research into human clinical research represents a significant development milestone.

First-in-Human studies require carefully planned protocols, appropriate participant selection, experienced clinical teams, medical oversight and suitable infrastructure.

Scientia describes its team as First-in-Human early-phase experts and reports more than 300 studies completed since opening.

What Types of Studies Are Included in Early Phase 1 Development?

Early Phase I development can involve several study designs depending on the research question and characteristics of the investigational product.

The exact design depends on the investigational product, development objectives, available evidence and applicable regulatory requirements. Scientia has experience across these and other Phase I study designs.

Why Is Experienced Clinical Research Infrastructure Important?

Early-phase studies can involve complex protocols, intensive sampling, close participant observation and rapid decision-making.

For sponsors, the capabilities of the clinical research unit therefore matter.

Dedicated Phase I Expertise

Scientia is a dedicated Phase I clinical trial unit located in Sydney. The organisation operates as a not-for-profit and has a long history of early-phase clinical research experience.

Strong Medical and Emergency Support

Scientia has a dedicated Service Agreement with Prince of Wales Hospital and operates within the Randwick health precinct. The surrounding network includes Prince of Wales Hospital, Sydney Children's Hospital, Royal Hospital for Women, UNSW Sydney and the Lowy Cancer Research Centre.

Participant Recruitment Capabilities

Recruitment can be a critical consideration in clinical research.

Scientia reports experience recruiting both healthy volunteers and patient populations, supported by a network of referring physicians throughout New South Wales. Its patient recruitment capabilities can support studies that require access to specific disease populations.

Investigational Product Support

Scientia also operates an in-house Investigational Product Suite, including a purpose-built cleanroom and facilities for investigational product dispensing, storage and preparation. This can help integrate important investigational product activities within the clinical research environment.

What Role Does Australia Play in Early Clinical Development?

Australia is an established location for international clinical research.

According to Scientia's information for sponsors, Australia offers a highly regulated clinical research environment, internationally aligned standards, a diverse population and an efficient regulatory framework. Its geographic position can also be useful for certain seasonal studies because Australia's seasons differ from those in the Northern Hemisphere.

For international sponsors, these factors can make Australia worth considering when planning early clinical development.

Scientia's Sydney location within the Randwick health precinct also provides access to major healthcare, research and academic institutions.

What Should Sponsors Consider Before Starting an Early Phase 1 Study?

Careful preparation can help ensure that an early clinical study is appropriately designed and operationally ready.

Sponsors should consider:

1. Study objectives – Clearly define the questions the study needs to answer.

2. Study population – Determine whether healthy volunteers or patients are appropriate.

3. Dose strategy – Establish an appropriate dose-escalation and monitoring approach based on the available evidence.

4. PK/PD requirements – Identify the samples and assessments needed to answer the development questions.

5. Safety monitoring – Define appropriate safety assessments and medical oversight.

6. Recruitment strategy – Assess whether the clinical research unit can access the required participant population.

7. Investigational product management – Plan storage, preparation, dispensing and accountability requirements.

8. Regulatory and ethical requirements – Ensure the study is prepared and conducted in accordance with applicable requirements.

9. Site capabilities – Evaluate the facility, medical team, emergency support and operational experience.

10. Data quality and timelines – Establish processes that support reliable data collection and efficient study execution.

A clinical research partner should be able to work collaboratively with the sponsor and adapt study execution to the specific requirements of the investigational product and protocol.

How Scientia Clinical Research Supports Early-Phase Development

Scientia Clinical Research focuses on early-phase clinical research and works with pharmaceutical and biotechnology companies on a range of Phase I studies.

Its experience includes:

• First-in-Human SAD and MAD studies

• PK and PD studies

• Food-effect studies

• Drug-drug interaction studies

• Bioequivalence studies

• Biosimilar and vaccine studies

• Ethno-bridging studies

• Phase I oncology studies

• First-in-patient studies

• First-in-human medical device studies

Scientia also states that it intentionally conducts a limited number of clinical trials each year, allowing its team to provide focused support and tailor its approach to individual sponsor requirements.

This combination of early-phase experience, participant recruitment capability, medical oversight and dedicated infrastructure can be particularly relevant when sponsors are planning complex First-in-Human or early development programs.

Moving New Treatments Forward With Early Clinical Evidence

An Early Phase 1 Clinical Trial is an important step in translating an investigational medicine from preclinical development into human research. By generating structured data on safety, tolerability, pharmacokinetics, pharmacodynamics and other study-specific endpoints, early-phase research can help sponsors make better-informed decisions about the next stages of development.

The quality of the clinical research environment matters throughout this process. Appropriate infrastructure, experienced investigators, participant access, medical oversight and operational flexibility can all contribute to effective study execution.

For sponsors evaluating an early-phase clinical development program in Australia, Scientia Clinical Research offers dedicated Phase I capabilities and experience across a broad range of early clinical study designs.

Ready to Discuss Your Early-Phase Study?

If you are planning a First-in-Human, Phase I or other early clinical development program, speak with the Scientia Clinical Research team to discuss your study requirements, participant population and operational needs.

Frequently Asked Questions

What is the main purpose of an Early Phase 1 Clinical Trial?

The main purpose is to generate initial clinical information about an investigational product, including safety, tolerability, pharmacokinetics and, where relevant, pharmacodynamic effects.

Are Phase 1 trials conducted only in healthy volunteers?

No. Many Phase I studies involve healthy volunteers, but some early-phase studies are conducted in patients, particularly when the investigational product or disease area makes patient participation more appropriate.

What is a First-in-Human study?

A First-in-Human study is an initial clinical study in humans involving an investigational product. It is designed to generate carefully controlled clinical data that can guide further development.

What are SAD and MAD studies?

SAD stands for Single Ascending Dose, while MAD stands for Multiple Ascending Dose. SAD studies investigate single doses across planned dose levels, while MAD studies evaluate repeated administration across planned dose levels.

What information can Phase I studies provide?

Depending on the protocol, Phase I studies can provide information about safety, tolerability, pharmacokinetics, pharmacodynamics, dose-related responses and interactions with food or other medicines.

Why is participant recruitment important in early-phase research?

Appropriate recruitment is essential because studies need participants who meet predefined eligibility criteria. Access to healthy volunteers or specific patient populations can affect study feasibility and timelines.

Why choose Sydney for early-phase clinical research?

Sydney provides access to a large healthcare and research ecosystem. Scientia is located in the Randwick health precinct and has access to a network of hospitals, researchers and referring physicians across New South Wales.